معرفی
Professor David Greening is Head of Molecular Proteomics at Baker Heart and Diabetes Institute and leads the Baker Department of Cardiovascular Research, Translation and Implementation at La Trobe University. He holds affiliate positions at Monash University and University of Melbourne, and serves as Director of the Proteomics and Metabolomics Platform at La Trobe University.
His educational background includes a BSc(Hons) and PhD from the University of Melbourne, followed by postdoctoral training at Ludwig Institute for Cancer Research, La Trobe University, and Institute for Systems Biology in Seattle. He completed Biomedical Research Management certification at the University of Melbourne in 2014.
Professor Greening's research focuses on extracellular vesicle (EV) biology and their therapeutic applications in cardiovascular disease. His laboratory employs advanced proteomics, mass spectrometry, and nanobiotechnology to understand EV mechanisms and develop next-generation cell-free therapies. Key research areas include engineering EVs for cardiovascular therapeutics, developing EV-based diagnostics, understanding cardiac remodeling using human cardiac organoids, and repairing cardiac tissue through exosome-mediated regeneration.
His publication record includes 148 papers with over 24,500 career citations and an h-index of 52, with work published in top journals including Nature Methods, Circulation Research, and Journal of Extracellular Vesicles. His research demonstrates strong trends toward therapeutic applications of EVs, particularly for cardiac repair, and the development of proteomic technologies to understand complex biological systems.
- Helen Amelia Hains Fellow and Baker Fellow
- Australian Field Leader (outright) – Proteins, Proteomics
- Chair, International Society of Extracellular Vesicles Congress (2024)
- Highly Cited Researchers 2020 (top 1%) by Stanford University
- International Protein Society Hans Neurath Outstanding Promise Award
- ROYAN International Research Award on Stem Cell Biomedicine
Professor Greening has established significant industry collaborations with Tithon Biotech, Takeda Pharma, and Thermo Fisher Scientific. He has successfully mentored numerous students and researchers, with his lab comprising molecular biologists, cell biologists, proteomics specialists, and clinical scientists working collaboratively. His research has advanced to pre-clinical and clinical utility with several commercialization outcomes.
The Molecular Proteomics laboratory operates as a multidisciplinary team focused on understanding EV function and developing innovative proteomic technologies. They collaborate extensively with national and international partners in biotechnology, proteomics, and regenerative medicine fields, maintaining strong industry networks that facilitate translation of basic research findings into clinical applications.
